| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 01/28/2004 | CN1471400A Combination therapy for the treatment of estrogen-sensitive disease |
| 01/27/2004 | US6683163 Monitoring angiogenesis factor |
| 01/27/2004 | US6682890 Methods of diagnosing and determining prognosis of colorectal cancer |
| 01/27/2004 | US6682730 Transplants for myocardial scars |
| 01/22/2004 | WO2004008123A1 Method and apparatus for 3-d imaging of internal light sources |
| 01/22/2004 | WO2004007440A1 Imaging compounds |
| 01/22/2004 | WO2004006979A2 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes |
| 01/22/2004 | WO2004006966A1 Steroid conjugates, preparation thereof and the use thereof |
| 01/22/2004 | WO2004006965A2 Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging for representing intravascular thrombi |
| 01/22/2004 | WO2004006964A1 Microbubble compositions, and methods for preparing and using same |
| 01/22/2004 | WO2004006963A1 Conjugated infrared fluorescent substances for detection of cell death |
| 01/22/2004 | WO2004006860A2 Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| 01/22/2004 | WO2004006854A2 Method for identification of biologically active agents |
| 01/22/2004 | WO2004006663A1 Hepatic cirrhosis model animal and method of constructing the same |
| 01/22/2004 | WO2003097107A3 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 01/22/2004 | WO2003092590A3 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| 01/22/2004 | WO2003014380A3 Microoroganisms and cells for diagnosis and therapy of tumors |
| 01/22/2004 | US20040015062 Fluorescence-mediated molecular tomography |
| 01/22/2004 | US20040014964 Vitronectin receptor antagonist pharmaceuticals |
| 01/22/2004 | US20040014706 Using protein antagonist; therapy for congestive heart failure; blocking gene expression |
| 01/22/2004 | US20040014656 Method for diagnosing neuronal deseases and for treating primary hemostasis deficiency |
| 01/22/2004 | US20040014096 Comprising a fluorescent label and a quencher of that fluorescent label, wherein the quencher is attached to a phosphate moiety that is cleaved off when the nucleotide is enzymatically incorporated into a polynucleotide |
| 01/22/2004 | US20040014024 Use of stable cell lines genetically engineered to express a recombinant fibroblast growth factor receptor (FGFR) |
| 01/22/2004 | US20040013687 Complexing Clostridium botulinum; translocation; induction immunology response |
| 01/22/2004 | US20040013668 Polypeptide antibody which binds to low density lipoprotein; quantitative analysis |
| 01/22/2004 | US20040013662 Microbubble compositions and methods for oligonucleotide delivery |
| 01/22/2004 | US20040013647 Methods and compositions for treating a plaque-forming disease |
| 01/22/2004 | US20040013639 Injecting radiopaque material together with hydrogel having various visible dyes into the milk ducts for mapping and identifying |
| 01/22/2004 | US20040013607 Conjugated to Y-90 through aminohexyl diethylenetriaminepentaacetic acid chelating agent |
| 01/22/2004 | CA2532324A1 Microbubble compositions, and methods for preparing and using same |
| 01/22/2004 | CA2492662A1 Method for identification of biologically active agents |
| 01/22/2004 | CA2492483A1 Method and apparatus for 3-d imaging of internal light sources |
| 01/22/2004 | CA2492475A1 Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| 01/22/2004 | CA2492297A1 Steroid conjugates, preparation thereof and the use thereof |
| 01/22/2004 | CA2491933A1 Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging for representing intravascular thrombi |
| 01/21/2004 | EP1382605A2 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands |
| 01/21/2004 | EP1382332A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent |
| 01/21/2004 | EP1381678A2 Nucleic acid modification enzymes |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381604A2 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 01/21/2004 | EP1381395A2 Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject |
| 01/21/2004 | EP1381311A2 Methods and reagents to acquire mri signals and images |
| 01/21/2004 | EP0941129B1 Process for the production of iodinated organic x-ray contrast agents |
| 01/21/2004 | EP0914165A4 Steroids as neurochemical stimulators of the vno to alleviate symptoms of pms and anxiety |
| 01/21/2004 | CN1469757A Use of metal complexes containing perfluoroalkyl as contrast agents in MR-imaging for the representation of plaques, tumours and necroses |
| 01/21/2004 | CN1469736A Use of a porous carrier |
| 01/20/2004 | US6680372 Antibodies specific for growth differentiation factor-7 |
| 01/20/2004 | US6680328 Cholinergic ligands of nicotinic acetyl choline receptors for treatment of central nervous system disorders, smooth muscle contraction disorders, endocrine diseases/disorders, neurodegeneration, inflammation, pain, and drug withdrawal |
| 01/20/2004 | US6680211 Fluorescent nanocrystal-embedded microspheres for fluorescence analysis |
| 01/20/2004 | US6680047 Diagnostic/therapeutic agents |
| 01/20/2004 | CA2090961C Specific binding agents |
| 01/15/2004 | WO2004005889A2 Detection of drug-resistant human immunodeficiency virus |
| 01/15/2004 | WO2004005531A2 Targeting and tracking of cells to specific organs and tissues in vivo |
| 01/15/2004 | WO2004005484A2 Snrks as modifiers of chk and branching morphogenesis and methods of use |
| 01/15/2004 | WO2004005464A2 Compounds promoting delivery of genes |
| 01/15/2004 | WO2004005320A2 ErbB-2 RECEPTOR TARGETING PEPTIDE |
| 01/15/2004 | WO2004004786A1 Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
| 01/15/2004 | WO2004004785A1 Mchks as modifiers of the chk1 pathway and methods of use |
| 01/15/2004 | WO2004004784A1 A complex of tumor ablation mixture and its use in the preparing drugs for treating tumors |
| 01/15/2004 | WO2004004757A1 Treatment for eye disorder |
| 01/15/2004 | WO2004004693A1 Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| 01/15/2004 | WO2004004636A2 Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
| 01/15/2004 | WO2003090604A3 Method of endovascular brain mapping |
| 01/15/2004 | WO2003057148A3 Use of biomolecular targets in the treatment and visualization of tumors |
| 01/15/2004 | WO2003014383A3 Phenotypic effects of ubiquinone deficiencies and methods of screening thereof |
| 01/15/2004 | US20040010192 Optical imaging of induced signals in vivo under ambient light conditions |
| 01/15/2004 | US20040009212 .2-.5% of a mucoadhesive polymer of carboxylvinylpolyester (i.e. carbopol or carbomer) and celluloses, 15%-40% of a thermoresponsive polymer having two critical points and a balance of water |
| 01/15/2004 | US20040009124 Detection of drug-resistant human immunodeficiency virus |
| 01/15/2004 | US20040009122 A formulation V-L-R where v is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker or a bond and R is a detectable moiety (v is nonpeptidic or peptide and R is a macromolecule) |
| 01/15/2004 | CA2491484A1 Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
| 01/15/2004 | CA2491128A1 Treatment for eye disorder |
| 01/15/2004 | CA2490703A1 Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
| 01/14/2004 | EP1380295A1 Photosensitiser and method for production thereof |
| 01/14/2004 | EP1379885A2 Contrast enhancement agent for magnetic resonance imaging |
| 01/14/2004 | EP1379873A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 01/14/2004 | EP1379337A1 Generation of pharmaceutical agent particles using focused acoustic energy |
| 01/14/2004 | EP1379282A2 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders |
| 01/14/2004 | EP1379226A2 Animal model for evaluating analgesics |
| 01/14/2004 | EP0690991B2 Novel anticoagulant cofactor activity |
| 01/14/2004 | CN1468312A Chimeric gfp-aequorin as bioluminescent ca<++> reporters at the single cell level |
| 01/14/2004 | CN1468234A Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use |
| 01/14/2004 | CN1468113A Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof |
| 01/14/2004 | CN1467208A [18F] Fluorin marked pyridine compound and method for preparing the same and uses as dopamine D4 receptor developer |
| 01/13/2004 | US6677377 Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions |
| 01/13/2004 | US6676971 Crosslinked macromolecules |
| 01/13/2004 | US6676929 Medical diagnosis; gadofosveset |
| 01/13/2004 | US6676928 Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use |
| 01/13/2004 | US6676927 Animal model and methods for its use in the selection of cytotoxic antibodies |
| 01/08/2004 | WO2004002536A1 Methods and contrast agents useful in quantifying nitric oxide |
| 01/08/2004 | WO2004002499A1 Drug for prevention and/or treatment of constipation and symptom caused by constipation |
| 01/08/2004 | WO2004002468A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 01/08/2004 | WO2004002455A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 01/08/2004 | WO2004002454A1 Camptothecin-carboxylate formulations |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002308A2 Management of gastro-intestinal disorders |
| 01/08/2004 | WO2004002307A2 Management of gastro-intestinal disorders |
| 01/08/2004 | WO2003087165A3 Biocompatible materials and probes |
| 01/08/2004 | WO2003086178A3 Methods for inhibiting vascular hyperpermeability |
| 01/08/2004 | WO2003000859A3 G-protein coupled receptors |
| 01/08/2004 | WO2002060524A9 Enhanced ultrasound detection with temperature dependent contrast agents |